All articles tagged with #alpha synuclein
CWRU researchers link alpha-synuclein to mitochondrial dysfunction in Parkinsons by binding to the ClpP enzyme; they designed a CS2 decoy to block this interaction, reducing inflammation and restoring function in cells and animal models, offering a potential root-cause therapy with human trials possible in about five years.
Scientists show that alpha-synuclein directly binds the ClpP enzyme, sabotaging mitochondria and fueling neuron loss in Parkinson's models; they created CS2, a decoy that blocks this interaction, restoring mitochondrial function, reducing inflammation, and improving movement and cognition in tissue and animal models, with plans to advance toward human trials.
Researchers have identified that alpha-synuclein binds to the mitochondrial enzyme ClpP, impairing energy production and accelerating neuron loss in Parkinson’s disease. They developed CS2, a decoy therapy that blocks this interaction and restores mitochondrial function, showing reduced inflammation and improved movement and cognition in human tissue, patient-derived neurons, and mouse models. The work points to a disease-modifying treatment targeting a root cause, with plans to advance toward human trials in the next five years.
Parkinson's disease is discussed as a neurodegenerative condition linked to misfolded alpha-synuclein, with early non-motor signs such as reduced sense of smell and REM sleep behavior disorder often appearing years before tremors; evidence suggests initiation in the nose or gut with brain-wide spread, while environmental factors like air pollution, pesticides, and solvents may raise risk and drive prevention efforts. The Parkinson's Progression Markers Initiative aims to detect the disease earlier with biomarkers (e.g., alpha-synuclein assays) to speed treatments, but no current therapy slows progression; emphasis on exercise and sleep as important, potentially protective, interventions.
A UCLA-led study links long-term chlorpyrifos exposure to about a 2.74-fold increase in Parkinson's disease risk, based on 829 PD cases and 824 controls using California pesticide-use data and residence/work addresses; animal models show dopamine neuron loss and alpha-synuclein buildup with autophagy disruption, which can be mitigated by stimulating autophagy, supporting a likely causal link while noting many factors influence PD and that chlorpyrifos use persists in the US.
Scientists in the UK have developed a peptide that stabilizes alpha-synuclein, a protein linked to Parkinson's and dementia, preventing harmful clumping in the brain. In animal models, this approach reduced protein buildup and improved movement, offering a promising avenue for future treatments of neurodegenerative diseases.
A new study suggests that alpha-synuclein oligomers may damage brain cells by forming dynamic pores in cell membranes, potentially contributing to Parkinson's disease progression, and offers new insights into the disease's mechanisms and potential treatments.
A study links fine particulate air pollution (PM2.5) to Lewy body dementia by showing that exposure triggers toxic alpha-synuclein protein clumps in the brain, increasing disease risk and suggesting pollution as a potential target for prevention and treatment.
A recent study suggests that Parkinson's disease may originate in the kidneys rather than the brain, with abnormal alpha-synuclein proteins building up in the kidneys and potentially spreading to the brain, opening new avenues for understanding and treating the disease.
A study suggests that Parkinson’s disease may originate in the kidneys, where alpha-synuclein proteins accumulate and travel to the brain via nerve pathways, especially when kidney function is impaired, potentially explaining the link between kidney disease and increased Parkinson’s risk.
Researchers have identified how a surface protein called Aplp1 interacts with Lag3 to facilitate the spread of toxic alpha-synuclein in Parkinson's disease. An existing FDA-approved cancer drug targeting Lag3 has been shown to block this process in mice, suggesting a potential treatment for Parkinson's may already exist. Further testing on mouse models is planned to explore this promising approach.
Claudio Soto, a Texas scientist, has been awarded the Robert A. Pritzker Prize by the Michael J. Fox Foundation for his pioneering work in Parkinson's research. Soto developed the alpha-synuclein seed amplification assay (AlphaSyn-SAA), a technique that detects misfolded alpha-synuclein in cerebrospinal fluid, enabling early diagnosis of Parkinson's disease. This breakthrough has the potential to transform clinical trials and improve early detection and treatment of Parkinson's and other neurodegenerative diseases.
Researchers at the University of Cambridge have utilized AI and machine learning techniques to identify five promising compounds that prevent the harmful clumping of alpha-synuclein, a key protein in Parkinson’s disease. This AI-driven approach has accelerated the screening process tenfold and reduced costs significantly, potentially expediting the development of new treatments for Parkinson's. The findings represent a crucial advancement in drug discovery for neurodegenerative diseases, particularly Parkinson's, which affects over six million people globally and is projected to triple by 2040.
Researchers have used computational models to understand the aggregation of alpha-synuclein protein, a key factor in Parkinson’s disease development. The study reveals that environmental factors such as molecule crowding and ionic changes enhance aggregation through distinct mechanisms. This research not only advances our understanding of neurodegenerative diseases but also offers new avenues for exploring therapeutic interventions.
A skin biopsy test called Syn-One has shown promise in detecting alpha-synuclein clumps, a hallmark feature of Parkinson's disease and related conditions, with positive results in over 90% of patients in a recent NIH-sponsored clinical trial. The test, developed by CND Life Sciences, offers a less invasive and more convenient diagnostic pathway compared to traditional methods, such as spinal taps. The study's findings suggest that the Syn-One Test could be a valuable tool for early disease diagnosis and may aid in improving care for patients with synucleinopathies.